Form 4: Armata Pharmaceuticals CEO Deborah Birx Acquires Stock Options
SEC Form 4 Filing
Deborah Birx, CEO of Armata Pharmaceuticals, acquired 240,000 stock options on February 5, 2025, according to a Form 4 filing.
Summary
- A Form 4 filing reveals that Deborah Birx, the CEO of Armata Pharmaceuticals, acquired 240,000 stock options on February 5, 2025.
- The exercise price of these options is $2.04.
- The options vest in four equal installments of 25% on February 5th of each year from 2026 to 2029, contingent upon continuous service.
- The options expire on February 5, 2035.
- Following the transaction, Deborah Birx directly owns 240,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing related to executive compensation. The grant of options is generally viewed as a positive, aligning management with shareholders, but it's not overwhelmingly positive.
Positives
- The acquisition of stock options by the CEO could align her interests with those of the shareholders, incentivizing her to improve the company's performance.
Future Outlook
The vesting schedule of the options (25% annually from 2026-2029) suggests a long-term commitment from the CEO.
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value creation.
Comparison to Industry Standards
- Executive compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, performance, and stage of development.
- Comparing Armata's executive compensation structure to peers like Spero Therapeutics or Atea Pharmaceuticals could provide further context.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning the CEO's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of the stock option grant to Deborah Birx. |
| 02/05/2025 | Date of earliest transaction. |
| 02/05/2026 | First vesting date for 25% of the stock options. |
| 02/05/2027 | Second vesting date for 25% of the stock options. |
| 02/05/2028 | Third vesting date for 25% of the stock options. |
| 02/05/2029 | Final vesting date for 25% of the stock options. |
| 02/05/2035 | Expiration date of the stock options. |
| 02/07/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.